Evaluation of efficacy and safety of robotic stereotactic body radiosurgery and hypofractionated stereotactic radiotherapy for vertebral metastases

Księżniak-Baran, Dorota; Blamek, Sławomir; Roch-Zniszczoł, Agata; Stąpór-Fudzińska, Małgorzata; Miszczyk, Leszek

doi:10.5114/wo.2015.53371

Cited by 3 publications

(4 citation statements)

References 35 publications

(74 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Where both are reported, the TTP PR result was lower than for assessable patients only [(62% vs 82% (55), 47% vs 62% (74), 60% vs 69% (38), 77% vs 91% (32), 61% vs 93% (68), and 71% vs 88% (4, 61)]. Overall response rates for PR varied from 38% (n = 28) (34) to 100% (n = 18) (52) in assessable patients.…”

Section: Resultsmentioning

confidence: 98%

“…In the TTP analysis, the range of PR outcomes varied from 27% (n = 11) (34) to 98% (n = 52) (35). LC rates at 1 year ranged from 25% (n = 28 patients) to 95.5% (n = 64 lesions) (36,37).…”

Section: Resultsmentioning

confidence: 99%

“…All other grade 3–4 toxicities reported in prospective studies were treatment-related neurologic toxicity (39, 41, 46, 68). Of the 28 studies evaluating toxicity retrospectively, 5 grade 3 or 4 toxicities (0.002%) were observed in 2033 patients (22, 24, 25, 29, 30, 32, 34–36, 52–57, 59, 60, 66, 69–71, 73–77, 79, 80).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Systematic Review of the Role of Stereotactic Radiotherapy for Bone Metastases

Spencer¹,

Velden²,

Wong³

et al. 2019

JNCI: Journal of the National Cancer Institute

View full text Add to dashboard Cite

Background Stereotactic radiotherapy (SBRT) might improve pain and local control in patients with bone metastases compared to conventional radiotherapy, although an overall estimate of these outcomes is currently unknown. Methods A systematic review was carried out following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Pubmed, Embase, and Cochrane databases were systematically searched to identify studies reporting pain response and local control among patients with bone metastases from solid-organ tumors who underwent SBRT in 1–6 fractions. All studies prior to April 15, 2017, were included. Study quality was assessed by predefined criteria, and pain response and local control rates were extracted. Results A total of 2619 studies were screened; 57 were included (reporting outcomes for 3995 patients) of which 38 reported pain response and 45 local control rates. Local control rates were high with pain response rates above those previously reported for conventional radiotherapy. Marked heterogeneity in study populations and delivered treatments were identified such that quantitative synthesis was not appropriate. Reported toxicity was limited. Of the pain response studies, 73.7% used a retrospective cohort design and only 10.5% used the international consensus endpoint definitions of pain response. The median survival within the included studies ranged from 8 to 30.4 months, suggesting a high risk of selection bias in the included observational studies. Conclusions This review demonstrates the potential benefit of SBRT over conventional palliative radiotherapy in improving pain due to bone metastases. Given the methodological limitations of the published literature, however, large randomized trials are now urgently required to better quantify this benefit.

show abstract

Section: Resultsmentioning

confidence: 98%

“…In the TTP analysis, the range of PR outcomes varied from 27% (n = 11) (34) to 98% (n = 52) (35). LC rates at 1 year ranged from 25% (n = 28 patients) to 95.5% (n = 64 lesions) (36,37).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Systematic Review of the Role of Stereotactic Radiotherapy for Bone Metastases

Spencer¹,

Velden²,

Wong³

et al. 2019

JNCI: Journal of the National Cancer Institute

View full text Add to dashboard Cite

show abstract

“…PET-CT (18F-Choline-, 11C-Choline-, 11C-Octane-, 18F-NaF-, 18 F-DCFBC-PET-CT) showed to be more sensitive than bone scintigraphy, MRI or CT in case of bone metastases detection especially in patients with PSA concentration over 3 ng/ml but there is still no one "gold standard" imaging technique to delineate metastasized prostate cancer [7,8,9].…”

mentioning

confidence: 99%

CyberKnife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases.

Napieralska¹,

Miszczyk²,

Stąpór-Fudzińska³

2016

neo

View full text Add to dashboard Cite

The aim of the study was to evaluate the effectiveness and toxicity of CyberKnife (CK) stereotactic radiosurgery (SRS) and stereotactic ablative radiation therapy (SABR) of patients with prostate cancer bone metastases. Analysis of prognostic and predictive factors was also performed.Material consisted of 51 patients with 71 bone oligometastases treated using CK SRS/SABR. In half of the patients single lesion was treated, in half 2-5 lesions. Median PSA concentration at the time of metastasis detection was 5.75 ng/ml. Total dose of 6-45Gy (median 20) was delivered with 1-5 fractions of 6-15 Gy (median 9). Biologic equivalent dose (BED) (α/ β=1.6) over 100 Gy was delivered to 45 lesions (63%) in 38 patients (75%).In statistical analysis Kaplan-Meier method, log-rank test and the Cox proportional hazard model were used. One-, two-and three-year overall survival (OS) was 90%, 76% and 70%, respectively. All patients having PSA concentration lower that 1 ng/ml at last control lived at least three years. One-, two-and three-year local control (LC) was 97%, 70% and 30%. Patients with PSA below 20 ng/ml at the time of metastasis detection had better local control of lesions and lower PSA at the last control. Median of PSA concentration after CK based SRS/SABR remains stable during first 12 months of follow-up, dropped during the next months and at last control was comparable to initial level. Median PSA at last control in patients without disease progression was 1.67ng/ml and 20 patients had PSA below 1.0ng/ml. At the last control 59% of patients had no other metastases. Rapid pain decrease was observed in analysed group and during each control about 90% of patients had pain relief. No major toxicity was observed, 3 patients suffered from fracture of irradiated bone. SRS/SABR of prostate cancer bone oligometastases provides good LC of lesions, excellent pain control without additional toxicity. Patients with PSA concentration below 20ng/ml at the time of metastasis detection have better LC and PSA concentration response.

show abstract

Current approaches to radiotherapy for skeletal metastastic lesions

Bychkova¹,

Khmelevsky²

2019

Onkol. Z. im. P.A. Gercena

View full text Add to dashboard Cite

Evaluation of efficacy and safety of robotic stereotactic body radiosurgery and hypofractionated stereotactic radiotherapy for vertebral metastases

Cited by 3 publications

References 35 publications

Systematic Review of the Role of Stereotactic Radiotherapy for Bone Metastases

Systematic Review of the Role of Stereotactic Radiotherapy for Bone Metastases

CyberKnife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases.

Current approaches to radiotherapy for skeletal metastastic lesions

Contact Info

Product

Resources

About